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ABSTRACT 
 
A dispersive liquid-liquid microextraction (DLLME) method has been developed, 
optimized and validated for the extraction of seven beta-agonists (Cimaterol, 
Cimbuterol, Clenproperol, Clenbuterol, Ractopamine, Isoxsuprine and Ritodrine) 
from bovine muscle. The homogenized tissue samples were hydrolyzed 
enzymaticaly by beta-glucuronidase and extracted with DLLME.  The extraction 
parameters (pH, extraction solvent, extraction solvent volume, disperser solvent) 
were accurately optimized. 
 
Separation of the beta-agonists was by gradient elution on C18 LC column using 
acetonitrile and formic acid aqueous solutions as mobile phases, multiple reaction 
monitoring (MRM) scan mode was used.  The seven beta-agonists were then 
simultaneous determined and identified in single analysis using 4000 Qtrap LC-
MS/MS system.  The DLLME method was validated using ISO 17025 and the EU 
criteria (Commission Decision 2002/657/EC) for validation of analytical method, good 
precision, repeatability and spiked recoveries were obtained.  The limits of detection 
and quantification for the residues were between 0.0728 – 0.0922 µg/kg and 0.243 – 
0.307 µg/kg respectively for beta-agonists.  The overall recoveries were between 
85% and 100% with the relative standard deviation of (RSDs) between 3.0% and 
10%.  The recoveries from the developed DLLME method were compared with those 
obtained from dSPE.  DLLME proved to be comparable to SPE.  The real samples 
test showed that the DLLME method developed is accurate and sensitive for the 
determination of beta-agonist residues in bovine muscle.  
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CHAPTER ONE 
INTRODUCTION 
1.1  Background 
Beta-agonists are used in human for the treatment of pulmonary disorders. These 
drugs were also used for this application on meat producing animals before they 
were banned.  When used at higher concentrations in animals, they can act as 
anabolic steroids promoting muscle development at expense of fat deposition.  This 
ability to suppress fat deposition improves meat quality hence more gain to farmers 
leading to their abuse.  Their use in animal husbandry for exportation to EU mark is 
prohibited, hence sensitive and reproducible detection techniques are needed to 
control and monitor their residues in food.  
 
The European Union (EU), United States of America (USA), and some other 
countries have established Maximum Residue Limits (MRL) and/or Minimum 
Required Performance Level (MRPL) for veterinary drugs, including beta-agonists.  
Therefore, several countries have developed sensitive qualitative and quantitative 
methods for monitoring beta-agonists at trace levels in different matrices.  The 
analytical methods that are employed must be able to detect the beta-agonists 
residues at, or below, the MRL/MPRL.  The Liquid Chromatography Tandem Mass 
Spectrometry (LC-MS/MS) and Gas Chromatography Mass Spectrometry 
(GC-MS) are now commonly used methods as they are most suitable since they 
comply with the European Union Commission Decision 2002/657/EC, concerning 
requirements for confirmatory methods.  Screening methods such as enzyme-linked 
immunosorbent assay (ELISA) may show false-positive results due to matrix 
interference, hence require confirmatory methods. Analytical methods such as 
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ELISA as well as Gas Chromatography (GC) and Liquid Chromatography (LC) 
hyphenated to mass spectrometers (GC-MS, LC-MS, LC-MS/MS) have been 
developed for determination of beta-agonists at MRL/MRPL levels.  The MRPL for 
beta-agonists in bovine muscle has been set at 0.5 µg kg-1 by the EU while for 
animal feed it is 50 µg kg-1 [1]. 
 
1.2  Analytical methods used for Analysis of beta-agonists 
1.2.1 Sample preparation techniques for beta-agonists  
In most determinations, sample preparation utilises more than 60% of the total time 
required for the analysis. Modern analytical chemistry is moving towards 
miniaturization and simplified analytical procedures.  Hence continual development 
of sample preparation in analytical chemistry is vital.  The sample preparation steps 
in an analytical chemistry, may entail extraction, isolation and enrichment of analytes 
of interest from a sample matrix.  The most commonly used sample preparation 
techniques for analysis of beta-agonists in various matrices are solid phase 
extraction (SPE) and liquid liquid extraction (LLE) [2-4].  Dispersive solid phase 
extraction (dSPE) with various media C2 [5-6], C8 [7-8], C18 [9-11], immunoaffinity 
[12-16], diatomaceous earth [17-19], ion exchange columns [20-26] have also been 
used.  The major disadvantage of these sample preparation techniques is, the use of 
significant volumes (milliliters up to liter) of organic solvents.  Dispersive liquid-liquid 
microextraction (DLLME) has been applied for the first time for analysis of beta-
agonists in bovine muscle, since it is more economical viable for laboratories with 
high sample through put, to use less toxic organic solvent (uses microliter volume) 
and is easy to operate. 
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1.2.2  Detection techniques used for Analysis of beta-agonists  
Analysis of beta-agonists by GC-MS via various derivatization procedures has been 
reported [2, 27].  Unfortunately, derivatization is a complex and time-consuming 
procedure.  It has been observed that recoveries were adversely affected by 
incomplete derivatization of the compounds. High-performance liquid 
chromatography (HPLC) does not require a derivatization step hence can be an 
alternative to GC-MS analysis.  The HPLC technique have been extensively used in 
quantitative analysis of beta-agonists, using UV [28], fluorescence [29-30], 
electrochemical [31], and MS [32-35] as detectors.  A number of LC-MS/MS multi-
residue methods for the determination of up to seven beta-agonists in retina and liver 
have been previously reported [36-40].  The current procedure determines seven 
beta-agonists in bovine muscle using enzymatic digestion, LLE, and DLLME, 
followed by determination of the residues by 4000 Qtrap (+ESI/LC-MS/MS).  
 
1.3 Motivation for the Study  
The sample preparation techniques already in use, for Analysis of beta-agonists in 
various matrices are SPE, dispersive solid phase extraction (dSPE), quick easy 
cheap effective rugged and safe (QUECHERS) and LLE, use large volumes (in 
mililiters and above) of toxic organic solvents, which result in disposal being a 
problem. In laboratories with high sample throughput, these techniques become not 
economically viable for the routine analysis of beta-agonists. 
 
 
 
 
4 
 
1.4  Main Objective  
The objective of this study was the development of an efficient and economically 
viable, environmentally friendly, sample preparation (DLLME) method for the 
analysis of beta-agonists using LC-MS/MS. 
Specific Objectives  
(1) To develop and optimize LC-MS/MS method for the determination of 
beta-agonists.  
(2) Develop, optimize and validate the dispersive liquid-liquid 
microextraction (DLLME) method for the extraction of seven beta-
agonists.  
 (3) To apply the validated DLLME-LC-MS/MS method for the determination of 
beta antagonists in bovine muscle samples. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.0  Introduction 
Modern analytical research is oriented towards developing sample preparation 
methods which are efficient, environmentally friendly and economical.  However, the 
complexity of food samples matrices (matrix interferences) suppress this effort to 
determine residues of veterinary drugs at trace levels to satisfy food regulations.  
The wide array of food matrices, from liquids to solids, requires different sample 
preparation techniques for accurate and reproducible results.   
 
2.1 Origin and chemical properties of beta-agonists 
Beta-agonists are alkanolamines (aromatic beta-amino alcohols), compounds which 
contain both hydroxyl (-OH) and amino (-NH2, -NHR and –NR2) functional groups.  
They constitute a group of compounds such as clenbuterol, terbutaline, salbutamol, 
fenoterol, salmeterol, ractopamine, bromobuterol, cimaterol, clenpenterol, mabuterol, 
tulobuterol, mapenterol, cimbuterol, bambuterol, formoterol, orciprenaline, ritodrine, 
isoxsuprine, labetalol and penbutolol.  Beta-agonists are also known as beta-
adrenergic agonists [41].  An adrenergic agent is a drug that is capable of either 
stimulating (agonist) or inhibiting a response (antagonist).  This property made them 
gain popularity in pharmacology, particularly for their anti-inflammatory activities.  
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2.2  Use of beta-agonists 
In humans, beta-agonists are used as bronchodilators by asthmatic sufferers [42-44].  
These drugs mainly target the muscles around the airways (bronchi and 
bronchioles).  When these muscles tighten, they make the airways narrower, often 
leading to suffocation.  Administration of beta-agonists relaxes the muscles of the 
airways resulting in easier breathing.  They also have anti-inflammatory activity, 
which prevent the release and generation of mediators from human lung mast cells 
that can cause broncho-constriction and inflammation [45].  They can also be 
abused by athletes as performance-enhancing drugs.  Beta-agonists are 
administered in different ways in humans but the most common way through 
inhalation [42].  
 
2.3  Health effects of beta-agonists in humans  
Side effects of beta-agonists in humans include, increased heart rate and high blood 
pressure, anxiety, palpitation, as well as skeletal muscle tremors.  Also, a case of 
increased risk of death or near death from asthma associated with regular use of 
inhaled beta-agonist bronchodilators has been reported [42].  The effects of 
clenbutarol residues on consumers, especially those who might be taking prescription 
medication to relieve a pre-existing heart condition, may be detrimental [46]. In the 
improvement of carcass characteristics in animals and productivity by beta-agonists, 
the illegal use of beta-agonists has resulted in a number of reports on human food 
poisoning.  For example, in Spain in 2003 [47], Italy in 1997 and 2000 [48-49] and 
Portugal in 2005 [50], reports of human food poisoning were a result of the ingestion 
of liver and meat containing clenbuterol residues. 
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2.4  Legislation and monitoring of beta-agonists in food producing 
animals 
Beef exports to the European Union (EU) have played a major role in economic 
growth of emerging countries (including Botswana).  Regulations are in place to 
monitor and regulate the import of meat into the European community, which are to 
be followed.  There are measures in place to monitor certain substances (like 
veterinary medicines) and their residues in live animals and products for safety 
purposes [51-53].  The use of beta-agonists in veterinary medicine has only been 
allowed in the case of clenbuterol for bronchodilation in horses and calves, as well 
as tocolysis in cows [52-54].  The administration of beta-agonists in meat producing 
animals, as growth promoters, has raised concern in food health, since it leads to 
high concentration of residues in meat.  Beta-agonists fall under group A 
substances, i.e. prohibited substances in meat producing animals under Council 
Regulation 2377/90/EC.  As a result, no group A substances (beta-agonists 
inclusive) have been permitted in the European community for growth promoting 
usage in farm animals [44, 52, 54-56].  There are some countries such as South 
Africa, Asia and Mexico, which have approved the use of some of the beta-agonists 
(like Zilpaterol) in cattle as a growth promoter.  It becomes a challenge when the 
neighboring countries are regulating this abuse for EU market purposes [57].  
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2.5  Sample preparation Techniques 
2.5.1  Liquid liquid extraction 
Liquid-liquid extraction is an important sample preparation and/or clean-up 
technique, with a wide range of applications.  The extraction process is based on 
selective partitioning of beta-agonists components versus contaminants in the 
sample in two immiscible, or partially miscible, liquids.  This phenomenon is 
governed by the distribution coefficient.  There are many publications on the 
determination of beta-agonists using LLE as sample preparation technique [2, 4, 27] 
and other veterinary drugs residues (steroids and quinolones in food [2, 58]). 
 
2.5.1.1  Drawbacks of liquid-liquid extraction 
Liquid-liquid extraction has a number of disadvantages that limit its routine 
application  as a sample preparation technique [2].  These include large solvent 
volumes (i.e. 20 mL) [2, 4], limited selectivity, difficulty of automation and emulsion 
formation.  This technique works via solubility characteristics of the analytes, and 
relies on differential solubility of the analytes versus other sample matrix 
components.  Since the solvents used are typically non-polar organics, hydrophobic 
analytes are extracted into the organic layer, however non-polar interferences are 
often co-extracted.  Not only does this give a less pure extract than desired, but the 
co-extracts may accumulate on the analytical column, typically a reversed phase 
column. 
 
2.5.2  Principle of Solid-phase microextraction (SPME)  
Solid-phase microextraction (SPME) technique was introduced by Pawliszyn and co-
workers in the early 1990s, which allows simultaneous extraction and pre-
concentration of analytes from sample matrices [59-62].  It eliminates some 
disadvantages of conventional techniques such as solid-phase extraction (e.g. 
plugging of cartridges) and liquid-liquid extraction (e.g. use of toxic solvents) [62].  It 
is a solvent-less and rapid extraction technique that uses a fused-silica fiber, which is 
coated on the outside with an appropriate stationary phase.  The analytes in the 
sample (gaseous, liquid and solid) are directly extracted onto the fiber coating.  The 
SPME extraction process are: (1) partitioning of analytes between the extraction 
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phase and the sample matrix and (2) desorption of concentrated extracts into an 
analytical instrument [63].  Analyte extraction begins immediately after exposure to 
the vapour phase above a solution (Headspace-SPME) or direct immersion in the 
solution (DI-SPME).  Once equilibrium is reached between the analyte in the sample 
and on the fiber (analyte extraction and pre-concentration are combined in single 
step), the extraction process is complete.   
 
The extracted analytes were then desorbed into a sample vials for chromatographic 
analysis.  The SPME technique can be used routinely in combination with GC-MS, 
HPLC or LC-MS in different fields. SPME has gained popularity in routine analysis in 
laboratories and industrial applications in recent years [64-65]. Analysis of food 
samples [66-70], forensics [71-73], environmental analysis (such as pesticides, 
phenols, PCBs, PAHs) [74-79] and drug analysis [27, 80].  This technique is been 
continually developing in terms of new devices, essential parameters in SPME 
processes like fiber coating and nanotechnology application. 
  
2.5.3 Liquid phase microextraction 
LPME is a solvent miniaturized sample preparation procedure of LLE, where a few 
µL of solvent is used to concentrate analytes from various samples rather than 
hundreds of mL, needed in traditional LLE.  This sample pretreatment technique is 
compatible with a number of analytical instruments, gas chromatography (GC), 
capillary electrophoresis (CE) and HPLC.  The extraction normally takes place in the 
acceptor phase (water immiscible solvent), from the donor phase (an aqueous 
sample containing analytes). Its categories includes, single-drop microextraction 
(SDME), hollow-fiber microextraction (HF-LPME), and dispersive liquid-liquid 
microextraction (DLLME). 
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2.5.3.1 Single drop microextraction (SDME) 
SDME uses a microdrop (less than 5 µL) of an organic solvent to extract analytes 
from the sample solution.  After extraction, the microdrop is retracted back into the 
syringe and transferred for instrumental analysis.   
This type of microextraction may be applied to various analytical instruments and 
analytes with some modifications.  
 
          (a) DI-SDME                                       (b) HS-SDME 
Figure 2.5:  Diagram of a set for direct immersion single drop microextraction 
(DI-SDME) and headspace single drop microextraction (HS-SDME), 
(a ) and (b) respectively [81]. 
 
The HS-SDME follows the same basic principle as traditional SDME, but the drop of 
organic solvent is suspended in the vapor of a volatile sample in a closed vial. The 
analytes are extracted from the vapor above the liquid sample. HS-SDME has similar 
capabilities in terms of precision and speed of analysis as DI-SDME, but has the 
advantage of a wider variety of solvents to choose from.   
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The disadvantage of DI-SDME is the instability of the droplet at high stirring speeds.  
Fast agitation of the sample is employed to facilitate extraction efficiency since 
agitation allows continuous exposure of the extraction surface area to fresh aqueous 
sample and reduces the viscosity of the static layer [82].   
 
2.5.3.2  Hollow fiber liquid phase microextraction (HF-LPME) 
The HF-LPME was introduced by Pedersen-Bjergaard and Rasmussen [83].  This 
technique was developed from the basic principle of supported liquid membrane 
(SLM). Figure 2.6 illustrate the basic principle of HF-LPME.  
 
 
Figure 2.6:  A diagram of the structure of a set for hollow fiber liquid phase 
microextraction (HF-LPME) [82] 
 
The hollow fiber is first washed with acetone in an ultrasonic bath to remove any 
contaminants and dried in air. It is immersed in the organic solvent for a few minutes 
to fill its pores, and excess solvent is rinsed off with distilled water. The acceptor 
phase is carefully injected into the hallow-fiber with a microsyringe. 
 
The HF-LPME can be performed in either 2 or 3 phase modes, whereby in 2 phase 
mode the acceptor solution is an organic solvent (the same as the one used for the 
hollow fiber pores). In the two-phase LPME system, the target analytes are extracted 
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from the aqueous samples and into the organic solvent (acceptor solution) present 
both in the porous wall and inside the lumen of the hollow fiber.  The acceptor 
solution is then taken for instrumental analysis. In three mode,  the acceptor solution 
may be an acidic or alkaline aqueous solution.   
 
In three-phase LPME, the analytes are extracted from the aqueous sample, through 
the organic solvent in hollow fiber pores, and further into the aqueous acceptor 
solution present inside the lumen of the hollow fiber.  After extraction the aqueous 
acceptor solution is taken for instrumental analysis.  The first report on HF-LPME 
described the use of three-phase extraction, with methamphetamine as a model drug 
[83], while King et al. used two-phase HF-LPME for extraction of polyaromatic 
hydrocarbons from soil [84]. 
 
2.5.3.3  Principle of dispersive liquid liquid microextraction 
Dispersive liquid-liquid microextraction is a ternary component solvent system.  This 
method is based on:  
(1) An extraction solvent which is mixed with a dispersive solvent. The resulting 
solvent mixture is then rapidly injected into the aqueous sample. 
(2) The rapid injection of the extraction-dispersive solvent mixture produces a 
cloudy solution containing fine droplets (the analyte in the sample is extracted 
into the fine droplets) of extraction solvent fully dispersed in aqueous phase, 
(3) The analyte has to be in its neutral form for it to be extracted from the 
aqueous medium (sample) into the organic extraction solvent efficiently. 
Hence, for the case of beta agonists which exist as polar compounds with pK 
values greater than one, they need to be neutralized, by optimizing the pH of 
sample solution, in relation to their pK values.   
(4) The cloudy solution is then centrifuged, which causes the extraction phase to 
sediment at the bottom of the extraction tube, since the extraction phase 
solvent is heavier than water.  The enriched analytes in the sedimented phase 
are determined by either chromatographic or spectrometric methods.   
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DLLME has special requirements that must be fulfilled by the extracting solvent and 
disperser solvents.  The requirements for an extraction solvent are: (i) it must be 
immiscible with water and miscible in the dispersive solvent (ii) must have high 
extraction efficiency and selectivity for the target analyte (these analytes have to be 
in neutral form), (iii) must be more dense than water, (vi) must be compatible with the 
analytical instrumentation being used e.g. GC, GC-MS, HPLC or LC-MS/MS. (v) the 
volume of extraction solvent is very important, since variation affects the extraction 
efficiency. An increase in its volume, increases the volume of the sedimented phase, 
resulting in a decrease of the enrichment factor [85]. Figure 2.7 illustrate the basic 
principle of DLLME. 
 
 
Figure 2.7: The schematic diagram for DLLME process.  
 
The requirements for disperser solvent are: (i) the miscibility of disperser solvent in 
aqueous phase (sample) and organic phase (extraction solvent) is important. (ii) the 
volume of the disperser solvent plays an important role, due to the fact that its 
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variation causes changes in the sedimented phase volume.  At low volume of 
disperser solvent, the dispersion of the extraction solvent and cloudy solution, are 
not formed completely, while at high volumes, the solubility of analytes in water 
increases, therefore, the extraction efficiency decreases [85].  The application of 
dispersive liquid-liquid microextraction (DLLME) on aqueous samples for various 
organic compounds (including veterinary drugs) has already been done [55, 82-83, 
86-98] and tried in solid samples [99].  In this study it has applied to solid matrix 
(bovine muscle) for determination of beta-agonists. 
 
2.5.3.3.1 Comparison of DLLME with other microextraction techniques 
The DLLME, unlike SPME, does not need preconditioning, where the fiber must be 
pretreated for efficient extraction. The volume of the extractant microdrop in SDME is 
small – often not bigger than 5 µL, which confines the amount of analytes extracted 
and the extraction efficiency. DLLME is better since the extraction solvent volume is 
not limiting.  Furthermore, the microdrop in SDME is unstable and easily dislodged 
from the tip of the microsyringe needle during stirring.  Unlike in DLLME, the kind of 
extractant available for DI-SDME is limited, since it must satisfy certain conditions 
i.e. water immiscibility, appropriate density.  Compared to HF-LPME, DLLME has 
very short extraction times, mainly because of the large surface area between the 
solvents (disperser and extractor) and the aqueous phase. 
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2.5.3.3.2  DLLME and its application 
DLLME can be combined with other sample preparation techniques [88].  In some of 
the work in which matrices other than water were analyzed, the DLLME procedure 
acted more as a cleaning step than as a pre-concentration procedure.  When 
extracting complex solid samples, the eluate of an organic solvent that has been 
used to extract the analytes from a solid matrix [98,100-107] or from solid-phase 
extraction (SPE) containing the analytes [96-97, 108-110] that act as the disperser 
solvent in the DLLME system. It is from this basis (pre-treatement of solid samples 
before DLLME) that this study was developed. 
The objective of sample preparation is often not only to isolate and concentrate the 
target analytes (beta-agonists) from the samples (solid i.e. bovine muscle), but also 
to lower, or even, phase-out the interferences originally present in the sample. The 
interferences from matrix co-extractives components are often present in DLLME 
extracts, since it is not a selective extraction method. This is common when 
determining trace analytes in  complex matrices (e.g. bovine muscle).  This is the 
main reason behind reported applications of DLLME being solely focused on simple 
water samples, so exploration of potential applications of DLLME, with other sample 
preparation techniques, in more complex matrix samples is the main interest of this 
study. 
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Sample pre-treatment before the application of DLLME can be used to improve the 
selectivity and to improve the limits of quantification (LOQ) in the analysis of complex 
matrices like food and wastewater. The combination of SPE (as sample pre-
treatment) with DLLME, for the selective determination of chlorophenols in aqueous 
samples with various matrices, has been reported by Assadi et al [111]. 
 
2.5.3.3.3 Instruments coupled with DLLME 
 
As a novel sample preparation method, DLLME can be coupled with CE, GC, HPLC, 
AAS and LC-MS/MS [87, 96].  It has been widely applied to the determination of 
organic compounds [95, 112] and heavy metals [113].  
 
2.6  Analytical methods for the determination of beta-agonists 
The development of radioimmunoassay (RIA) as an extremely sensitive technique 
for the detection and quantification of very small concentrations of endogenous 
compounds in biological matrices, caused a revolution in clinical chemistry.  Since 
then, this analytical method has made its way into other disciplines, including 
veterinary drug residue (like beta-agonists) analysis [114].  Enzyme-linked 
immunosorbent assays (ELISA) encompass all solid-phase immunoassays using 
enzyme-labeled reagents.  Three versions are commonly used in food analysis: (1) 
direct competitive ELISA, (2) indirect ELISA, and (3) double-antibody or sandwich 
ELISA.  All these techniques have been used for the determination of beta-agonists 
residues in animals [114].  However, there are some drawbacks associated with 
ELISA, due to interferences in complex biomatrices such as meat, which frequently 
lead to low recovery and false-positive/negative results.  There is therefore a need to 
confirm the results with more precise techniques, like HPLC, GC and LC-MS/MS [57, 
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115-116].  Furthermore, there are instances of cross-reactivities (undesired side-
reactions) [67].  ELISA also has some limitation in multi-compound determinations, 
since it is compound specific [117].  The use of HPLC with different detectors, GC-
MS and LC-MS/MS for determination of beta-agonists has been reported [116].  
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CHAPTER THREE 
3. EXPERIMENTAL 
3.1 Material and Reagents 
HPLC grade acetone, ethanol, methanol, dichloromethane, chloroform, 
trichloromethane, tetrachloroethylene, formic acid and 2-propanol (Merck, 
Darmstadt, Germany) were used in this study.  LC-MS grade acetonitrile, sodium 
acetate and ammonium formate (analytical reagent grade) were obtained from 
Sigma-Aldrich (Munich, Germany).  Ultra high purity (UHP) water, with a resistivity of 
18.2 MΩcm-1, was obtained using a Milli-Q system Millipore Corp., (Molsheim, 
France). The following standards; ritodrine chloride (95.5%), isoxsuprine chloride 
(99.1%), clenbuterol chloride (95.5%), ractopamine chloride (95.5%), cimaterol 
(99.8%), cimbuterol (99.9%), clenproperol (99.9%) and β-glucuronidas were 
obtained from Sigma-Aldrich (Munich, Germany).  Table 3.1  summarizes the 
chemical structures, m/z, pKa values (1&2) and CAS numbers of all the beta-
agonists in this study.  
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Table 3.1 Name, chemical structure, physical properties and CAS numbers of all the 
beta-agonists in this study. 
 
Name Structure pKa1 pKa2 CAS number 
Cimaterol 
N
H
CN
H2N
OH  
m/z = 220 
13.7
5 
9.24 54239-37-1 
Cimbuterol 
H
N
OH
CN
NH2
CH3
H3C
H3C
 
m/z = 234 
   
Clenproperol 
H
NCl
Cl
H2N
OH
H3C
 
m/z = 263 
  38339-11-6 
Clenbuterol 
H
NCl
H2N
Cl
OH
H3N
 
m/z = 278 
9.63 14.06 37148-27-9 
Ractopamine 
H
N
H3C
HO
HO
OH
 
m/z = 302 
9.4  97825-25-7 
20 
 
Name Structure pKa1 pKa2 CAS number 
Isoxsuprine 
H
N
O
OH
H3C
HO H3C  
m/z = 302 
8 9.8 0000395-28-8 
Ritodrine 
m/z = 288 
9.15 9.81 26652-09-5 
 
 
H
N
HO
HO
H3C OH
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3.2 Sampling and storage of samples 
The bovine muscle samples used in this work were sampled from two Botswana 
Meat Commission (BMC) abattoirs, at Lobatse (South region) and Francistown 
(North region), as well as in different district municipal abattoirs.  Sampling was 
performed in accordance with the Commission Decision 98/179/EC of February 1998 
[123] and Directive 2002/63/EC or superseding legislation.  The fresh samples were 
packaged in polythene bags, placed in cooler boxes with ice packs and transported 
to the laboratory within 24 hours.  The samples were assessed upon arrival in the 
laboratory, to check if they were fit for laboratory testing, then passed on to the 
residues testing unit. The bovine muscle samples used in this study, were cut into 
smaller portions before being frozen (at ≤ - 20 °C) to avoid thawing and cutting of 
samples which compromises sample integrity.   
 
3.3 Instrumentation 
The LC-MS/MS system consisted of an Agilent 1200 HPLC system from Agilent 
Technologies (Waldbronn, Germany) and an Applied Bio-systems 4000 Qtrap mass 
spectrometer (Darmstadt, Germany) with Turbo VTM Ion source mass spectrometer 
(MS/MS).  The Agilent 1200 HPLC system consisted of an auto-sampler, a 
quaternary pump and a thermostated column compartment.  Analyst 1.5.2 software 
was used for instrument control and data processing. 
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Precisa 220M (Lancashire, United Kingdom) and Adam PGM 253e (Bletchley, 
United Kingdom) analytical balances were used for weighing the reagents and 
samples that were used in the experiments.  RADWAG AS 220/c/2 Supermicro 
balance (Bracka, Poland) was used to weigh analytical standards during standards 
preparation.  The samples were centrifuged in a Herus Biofuge PrimoR centrifuge 
Thermo Electron Cooperation (Steingrund, German).  Mettler Toledo (seven Multi) 
pH meter (Greifensee, Switzerland) was used for pH measurements. TurboVap 
(Turbo vap LV) Casper Life Sciences Automatic concentrator (Hopkinton Mass, 
United State of America) was used for evaporating the solvents during sample 
preparation. 
 
3.4 Standard solutions 
Standard solutions of cimaterol, cimbuterol, clenbuterol, clemproperol, isoxsuprine, 
ractopamine and ritodrine were individually prepared, by dissolving 10 mg in 10 mL 
of methanol, to make a 1 mg mL-1 stock solution, which was then stored at -20 °C.  
All standards were prepared by taking into consideration the percentage purity of 
standard and salt content.  The intermediate standards and working standards were 
prepared from the stock standards.  The intermediate and working standards were 
stored in a fridge (2 °C to 6 °C). 
3.4.1 Preparation of calibration and spiking solutions 
The standard solutions for the calibration curve and spiking experiments were 
prepared in methanol.  The calibration standards were made by serial dilution of the 
stock solution and the calibration curves were calculated using the linear regression 
model.  The spiking levels were 0.5, 0.75 and 1.0 µg kg-1.  
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3.5 Method development MS/MS conditions 
A 1.0 µg mL-1 standard mixture of seven Beta-agonists standards was diluted 100 
times by drawing up 100 µL into the syringe, then emptying the syringe followed by 
filling the syringe with 1 mL of methanol (0.1% formic acid).  This mixture was 
infused at 10 µL min-1, using an infusion pump (11 plus) ABI into mass spectrometer 
with Q1 scan (to confirm the presence of compounds of interest). Having entered the 
calculated mass of each analyte, with a width of 50 Da, a peak at [M + H]+ was 
obtained.  Compound optimization for each beta-agonist compound was run after 
observing a peak at [M + H]+. The MS optimizes the ion path for the beta-agonists 
compounds by ramping the ion optic voltages from low to high and determining the 
optimum value.  It also determines the most intense fragments, with their respective 
collision energies and creates an MRM method. 0.01 µg mL-1 of seven Beta-agonists 
standard mixture was used for optimization of the ion source and gas parameters 
(Gases, IonSprayTH Voltage &  temperature) and MRM scan mode was used.  
 
3.5.1  Ion source optimization parameters for beta-agonists 
The ion source parameters to be optimized are given in Table 3.51.  It is of 
paramount importance to optimize the ion source parameters for mass spectrometry 
analysis, for the method to be selective and specific. The standard mixture (10 µg L-
1) of beta-agonists was infused (using syringe pump with flow rate of 100 µL min-1) in 
to the mass spectrometer with Q1 scan to obtain [M + H]+. 
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Table 3.5.1: The ion source parameters to be optimized 
Ion source parameters 
IonsprayTM Voltage (IS) Collision Gas (CAD) 
Curtain GasTM (CUR) Declustering Potential (DP) 
Temperature (TEM) Entrance Potential (EP) 
Ion Source Gas 1(GS1) Collision Energy (CE) 
Ion Source Gas 2(GS2) Collision Cell Exit Potential (CXP) 
 
3.5.2 Optimization of compound dependent parameters for beta-agonists  
The following compound dependent parameters are to be optimized: a. Declustering 
Potential (DP), b. Entrance Potential (EP), c. Collision Energy (CE), d. Collision Cell 
Exit Potential (CXP). 
It is important that when developing a method with mass spectrometry analysis, the 
precursor ion, [M+H]+ when using positive ionization mode or [M-H]- when using 
negative ionization mode is observed before optimizing the compound dependant 
parameters of the mass spectrometer. This is to assure that a proper molecule is 
detected. In this instance, all the precursor ions for the seven beta-agonists studied 
were the predominant peaks in the spectra observed after infusion.  This was 
achieved by Q1 scan. 
 
3.5.2.1 Multiple Reaction Monitoring (MRM) scan 
This scan type was performed during compound optimization parameters of the 
mass spectrometer.  Moderate collision energy (52 volts) was used hence precursor 
ions were observed, for instance in the cimaterol case, the 220.2 ion was optimum. 
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3.5.2.2 The product Ion scan of cimaterol 
The product ion scan is an MS/MS scan, where the first Quadrupole (Q1) is fixed 
and the third Quadrupole (Q3) sweeps a range.  It is an experimental tool used to 
search for all products of a particular precursor ion (instant 220.2 ion).  The collision 
energy of the Q2, which is a collision cell, was ramped incrementally, from 52 volts to 
92 volts.  At low CE values, high molecular weight (MW) product ions are formed and 
most of the precursor ion are kept intact, whereas increasing the CE to higher 
values, low MW product ions are formed.  
 
3.6  HPLC separation of seven beta-agonists 
A phenomenex Luna Kinetex (150 x 3 mm I.D., 5 μm particle size) analytical column 
(Aschaffenburg, Germany) was used at constant temperatures of 30 °C and the 
sample injection volume was 10 μL.  Mobile phase A consisted of 0.1% v/v formic 
acid at pH 3.83, whereas mobile phase B consisted of acetonitrile with 0.1% v/v 
formic acid at pH 3.56 (50:50, v/v).  The pH of the formic acid was adjusted with 40 
mMol ammonium formate buffer.  The flow rate of the mobile phase was 0.25 mL 
min-1.  A gradient elution method was used with solvent A starting at 80% and held 
for 2 min, then dropped to 60% in a minute and held for 2 min.  The mobile phase 
composition was then raised to 80% solvent B in 3 min and maintained for 2 min 
before next injection. 
 
3.7. Sample preparation before DLLME procedure  
The homogenized muscle samples (2.0 ± 0.02 g) were placed in 50 mL 
polypropylene centrifuge tubes and spiked with 0.5, 0.75, 1.0 µg kg-1 of the standard 
solution mixture of containing seven beta-agonists.  A 10 mL aliquot of 0.2 M acetate 
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buffer, at pH 5.00, was added to the samples and gently mixing, then vortexed for 4 
minutes. A 40 µL aliquot of β-glucuronidase was then added, for enzymatic 
hydrolysis, before incubation for 2h at 40 °C for 2h.  The supernatant was decanted 
and placed in another container, where 0.8 g sodium chloride, 0.4 g sodium sulphate 
and 0.2 g magnesium sulphate, were added.  The sample was then centrifuged at 
4000 rpm for 10 min.  The resulting supernatant was filtered using 0.45 µm nylon 
filters and the pH adjusted to 11 with 40 mMol ammonium formate. 
 
3.7.1 DLLME procedure 
For DLLME, the pH, disperser solvent, extraction solvent and the volumes of both 
the disperser and extraction solvents were optimized.  
 
3.7.1.1 pH optimization 
The extraction of the analytes was investigated between pH 8 and 12 since the pKa 
values of the compounds under study were within this range. Using a 5 mL 
supernatant aliquot of sample, 1mL of 2-propanol (as disperser solvent) and 100 µL 
of chloroform (as extractor solvent), were used as the standard sample volume to 
optimize pH. 
 
3.7.1.2 Selection of disperser solvent 
Ethanol, methanol, acetonitrile, acetone and 2-propanol were investigated as 
possible disperser solvents.  The extraction conditions used in this study were; 5 mL 
supernatant aliquot at pH 11, 1 mL of disperser solvent and 100 µL of the extraction 
solvent.  
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3.7.1.3 Optimization of disperser solvent volume 
The effect of the volume of disperser solvent on the extraction efficiency was studied 
using 5 mL supernatant aliquat at pH 11, while varying the volume of disperser 
solvent (500-2500 µL) and 100 µL of extractor solvent. 
 
3.7.1.4 Selection of extraction solvent 
Four extraction solvents; chloroform, dichloromethane, tetrachloroethylene and 
trichloromethane were investigated.  A 5 mL of sample supernatant at pH 11 and 1 
mL of disperser solvent, while varying the volume of extractor solvent, were used in 
the experiments. 
 
3.7.1.5 Optimization of extraction solvent volume 
Different volumes of extraction solvent (dichloromethane), in a range of 50-200 µL 
were investigated. The extraction conditions, 5 mL supernatant aliquot at pH 11, 1 
mL of acetonitrile disperser solvent, were used. 
 
The DLLME procedure was, therefore, as follows: 1 mL of acetonitrile (disperser 
solvent) and 100 µL of dichloromethane (extraction solvent) were immediately 
injected into the 5 ml supernatant and thoroughly shaken to give a cloudy mixture.  
The mixture was then centrifuged and the sedimented solution was transferred into 
vials for LC-MS/MS analysis. 
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3.7.2 Validation of the optimized DLLME method  
The optimized DLLME method was validated according to the Commission Decision 
2002/657/EC and ISO 17025 [104]. The limit of detection (LOD), limit of 
quantification (LOQ), correlation coefficient (R2), accuracy and relative standard 
deviation, were used to express repeatability. In addition the decision limit (CC α) 
and detection capability (CC β), were calculated based on the MRLs of the 
compounds. The extraction recoveries and extraction efficiencies were also 
determined.  
3.7.2.1 Procedure for linearity 
Linearity was determined by spiking blank bovine muscle samples with beta-agonists 
standard mixture at concentractions corresponding to eight calibration levels in the 
range of 0.5 – 2.0 µg kg-1. A total of three spiked samples at each spiking level were 
taken through the entire DLLME procedure and used to construct a calibration curve. 
 
3.8  dSPE procedure 
The sample pre-treatment was as above (Section 3.7) up to enzymatic hydrolysis.  
The supernatant was decanted and placed into a Pyrex tube and 1.2 mL of 1 M HCl 
was added.  A 7 mL aliquot of sample extract was loaded onto a SPE A Strat-X-C 3 
mL/60 mg which had been previously conditioned with 2.0 mL of methanol and 
washed with 2.0 mL 0.1 M hydrochloric acid.  After loading the sample, the cartridge 
was washed with 1.5 mL 0.1 M HCL followed by 1.5 mL of methanol and finally 
eluted with 3 mL of ammonium hydroxide/methanol (5:95% v/v). The eluate was 
dried and reconstituted with the mobile phase for LC-MS/MS analysis. 
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CHAPTER FOUR 
 
4.0  Results and Discussion 
4.1.1.1 MS/MS method development 
A mass spectrometry method was developed and validated for the determination of 
seven beta-agonists.  It was achieved by optimizing the following parameters of the 
mass spectrometer: (i) ion source and (ii) compound dependent parameters. Table 
4.1.1 shows the ion source parameters for the beta-agonists. 
Table 4.1.1: Ion source parameters 
Ionspray parameter Optimized parameter 
IonsprayTM Voltage (IS) 4500 volts 
Curtain GasTM (CUR) 25 °C 
Temperature (TEM) 600 °C 
Ion Source Gas 1(GS1) 40 °C 
Ion Source Gas 2(GS2) 40 °C 
Collision Gas (CAD) Medium 
Declustering Potential (DP) 16 volts 
Entrance Potential (EP) 10 volts 
Collision Energy (CE) 25 volts 
Collision Cell Exit Potential (CXP) 14 volts 
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4.1.2 Compound optimization parameters for beta-agonists 
In this study, the precursor ions were predominant peaks in all seven beta-agonists 
of interest.  Compound optimization parameters for beta-agonists, obtained from 
Applied Biosystem API 4000 Qtrap mass spectrometer with Turbo VTM Ion source, 
LC-MS/MS in +ESI mode and MRM scan type, as shown table 4.1.2. These 
compound parameters allow the equipment to be very sensitive to detect and 
quantify these beta-agonists. Deviation from these parameters, for this equipment, 
will result in a loss in sensitivity. 
 
Table 4.1.2 Compound optimized parameters of beta-agonists in LC-MS/MS 
Compound Q1 Mass 
(Da) 
Q3 Mass 
(Da) 
Time 
(msec) 
Transitions DP 
(volts) 
EP 
(Volts) 
CE 
(Volts) 
CXP 
(volts) 
Cimaterol 220.3 160.1 150 Cimaterol T1 16 10 25 14 
143.1 150 Cimaterol T2 16 10 33 10 
116 150 Cimaterol T3 16 10 49 8 
 
Cimbuterol 234.3 160.1 150 Cimbuterol T1 11 10 21 10 
143.1 150 Cimbuterol T2 11 10 37 10 
116.1 150 Cimbuterol T3 11 10 49 8 
 
Clenbuterol 278.2 204 150 Clenbuterol T1 51 10 25 18 
203 150 Clenbuterol T2 51 10 23 16 
133 150 Clenbuterol T3 51 10 39 10 
 
Clenproperol 263.2 132 150 Clenproperol T1 11 10 37 10 
203 150 Clenproperol T2 11 10 27 18 
168.1 150 Clenproperol T3 11 10 39 14 
 
Isoxsuprine 302.3 107 150 Isoxsuprine T1 101 10 39 6 
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Compound Q1 Mass 
(Da) 
Q3 Mass 
(Da) 
Time 
(msec) 
Transitions DP 
(volts) 
EP 
(Volts) 
CE 
(Volts) 
CXP 
(volts) 
150.1 150 Isoxsuprine T2 101 10 31 12 
77 150 Isoxsuprine T3 101 10 85 12 
 
Ractopamine 302.3 164.2 150 Ractopamine T1 1 10 23 14 
107.2 150 Ractopamine T2 1 10 45 8 
121.2 150 Ractopamine T3 1 10 33 8 
 
Ritodrine 288.3 121.1 150 Ritodrine T1 96 10 33 8 
150.1 150 Ritodrine T2 96 10 27 12 
77.1 150 Ritodrine T3 96 10 77 4 
 
4.2.  LC Method development 
4.2.1 Liquid chromatography optimization 
A chromatographic separation method was developed for the determination of seven 
beta-agonists using. Phenomenex Luna Kinetex (150 mm x 3 mm,  5 μm analytical 
column, at a constant temperature of 30 °C.  The optimized chromatographic 
separation was achieved by changing different mobile phase (A and B) compositions 
and flow rates, one parameter at a time.  Figure 4.2 shows a typical chromatogram 
obtained for the separation of seven beta-agonists.  The linearity, correlation 
coefficient, limit of detection, limit of quantification, and the reproducibility were 
investigated. 
 
Figure 4.2.1 shows a chromatogram of formate buffered separation.  The seven 
beta-agonists were well resolved except ractopamine and isoxsuprine, which were 
co-eluting due to their isomerism (m/z of 302.3). The improved LC method was then 
used to validate the DLLME method. 
32 
 
 
XIC of +MRM (20 pairs): 220.348/160.100 Da ID: Cimaterol T1 from Sample 2 (50%ACN+EDTA 10mmol  STd 5ppb002) of Data03-10-1... Max. 9473.3 cps.
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Figure 4.2: Chromatogram of seven beta-agonists at 0.5 ppb concentration.  
 
The above chromatogram was as a result of developed separation method of seven 
beta-agonists under the study.  The developed separation method had some 
limitations, the ethylenediaminetetraacetic (EDTA) buffer was not suitable (since was 
not volatile) for LC-MS/MS analysis, was clogging the orifice of the ion source.  Also, 
the above method was less sensitive.  The EDTA buffer was then replaced with 40 
mM ammonium formate buffer, which is more volatile. 
33 
 
 
XIC of +MRM (20 pairs): 220.348/160.100 Da ID: Cimaterol T1 from Sample 2 (20130921b 01BBeta-Agonist calibration curve002) of Dat... Max. 4.4e5 cps.
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Figure 4.2.1: Separation of seven beta-agonists at 0.5 ppb level using ammonium 
formate buffer replacing EDTA buffer.  
 
The chromatogram in figure 4.2.1 indicates an improvement of sensitivity, shorter run 
time and no clogging of the orifice.  The seven beta-agonists were well resolved, 
except ractopamine and isoxsuprine, which were co-eluted, since they are isomeric 
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(m/z of 302.3) compounds. These compounds will still be quantified with ion 
abstraction using MRM mode, since they have same target ions but different 
daughter ions.  The improved LC method was then used to validate the DLLME 
method. 
 
4.3 DLLME Method development 
Dispersive liquid-liquid micro-extraction was selected as a sample extraction and/or 
clean-up method for beta-agonists in bovine muscle samples.  Extraction of analytes 
from bovine muscle is usually a challenge due to the presence of fat. The fat was 
removed by firstly treating the sample with salts and organic solvent prior to 
application of DLLME treatment. Parameters including extraction solvent, disperser 
solvent, sample pH as well as volume of extraction and dispersive solvents were 
optimised. 
 
4.3.1 Selection of extraction solvent 
The extraction solvent is one of the most important parameter that needs to be 
optimized for successful application of DLLME. Four extraction solvents were 
selected; chloroform, dichloromethane, tetrachloroethylene and trichloromethane for 
the extraction of beta-agonists.  Chloroform (1.48 g mol-1 at 20 °C), dichloromethane 
(1.34 g ml-1 at 20 °C), trichloroethane (1.33 g mol-1 at 20 °C) and tetrachloroethylene 
(1.62 g mol-1 at 20 °C) were used.  Dichloromethane was selected as the ideal 
solvent, since the extraction efficiencies ranged from 80 - 92% followed by 
chloroform with 70 – 88%, (Figure 4.3.1). Tetrachloroethylene and trichloromethane 
demonstrated low extraction efficiencies which were between 30 – 55% and 25 – 48 
% respectively.   
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Figure 4.3.1: Selection of extraction solvent for beta-agonists 
 
4.3.2: Selection of dispersive solvent 
The selection of the disperser solvent is also an important parameter in developing 
DLLME method.  In this study, five solvents were investigated as possible disperser 
solvents; 2-propanol, methanol, ethanol, acetonitrile and acetone.  Most beta-
agonists extracted well with acetonitrile, since the extraction efficiencies ranged from 
68 -90 % (Figure 4.3.2).  It was also observed that 2-propanol extracted reasonably 
well as a disperser solvent with extraction efficiencies ranging from 55 – 80%.  This 
disperser solvent (2-propanol) seemed to be the most efficient for isoxsuprine (78%) 
and cimaterol (79%), while the extraction efficiencies for the same analytes with 
acetonitrile were isoxsuprine (68%) and cimaterol (77%).  Methanol and acetone 
were not as efficient as disperser solvents with extraction efficiencies lower than 
50% for all analytes, this could be due to their less solubility in these solvents.  On 
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the basis of extraction efficiencies, acetonitrile was selected as disperser solvent for 
the extraction all of the beta-agonists. 
 
 
 
Figure 4.3.2 Selection of disperser solvent. 
 
4.3.3 pH optimization of DLLME for beta-agonists 
In dispersive liquid liquid micro-extraction, the analyte must be in its neutral form to 
be extracted from the aqueous phase (supernatant solution) and into the organic 
extraction solvent efficiently.  Beta agonists under study are polar compounds which 
need to be neutralized by optimizing the pH of sample solution in relative to their pKa 
values.  The partitioning of an analyte from an aqueous phase into a hydrophobic 
organic solvent, is greater for a neutral compound than for an ionized compound.   
 
The effect of pH on the extractability of beta-agonists was investigated in the range 
of 8 – 12.  Sodium hydroxide and formic acid solution were used to adjust the pH.  
The extraction efficiency at pH 8, 9, 10, 11 and 12, are illustrated in figure 4.3.3. 
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Cimaterol, cimbuterol, isoxsuprine and ritrodrine had the highest recoveries at pH 11, 
while, clenbuterol and clenproperol, at pH 12. The difference in the extraction of 
clenbuterol and clenproperol at pH 11 and 12 was very minimal, for example 
clenproperol had extraction efficiency of 90% and 95% at pH 11, 12 respectively. 6 
beta-agonist had extraction efficiency above 60% at pH 11, as compared to other pH 
levels hence pH 11 was selected as optimum pH for the extraction of beta-agonists.  
 
 
 
Figure 4.3.3. pH optimization of DLLME for beta-agonists in bovine muscle.  
 
 
4.3.4 Optimization of disperser solvent volume 
The volume of the disperser solvent plays an important role in the extraction of the 
analyte. Its variation has direct implications on the sedimented phase volume.  At low 
volumes of disperser solvent, the dispersion of the extraction solvent is poor and the 
emulsion formation is insufficient.   
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The effect of the volume of acetonitrile on the extraction efficiency was studied, and 
500- 2500 µL was selected.  The extraction efficiencies of the analytes in acetonitrile 
increased from 35-53 % at 500 µL to 73–85 % at 1000 µL.  The lower extraction 
efficiencies observed at 500 µL were due to an insufficient formation of the cloudy 
state, was not formed well.  However increasing the volume after 1000 µL resulted in 
a decrease in extraction efficiencies, from 51-72 %, 28-48% and 20 -31%, for 1500 
µL, 2000 µL and 2500 µL, respectively. This was due to an increase in the solubility 
of analytes in aqueous phase (high affinity of analytes to aqueous phase) thus 
leading to decrease in extraction efficiency [118-119].  Hence 1000 µL was selected 
as the disperser volume for all further work. 
 
 
 
Figure 4.3.4 Disperser solvent volume optimization 
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4.3.5 Optimization of extraction solvent volume 
The volume of extraction solvent is also very important parameter since, its variation 
affects the extraction efficiency and enrichment factors of analytes. In addition an 
increase in extraction solvent volume, increases the volume of the sedimented 
phase resulting in decrease of the enrichment factor [85].  Volumes of 
dichloromethane tested, as the extraction solvent, ranged between 50-200 µL were 
subjected to the same DLLME procedure.  Figure 4.3.5 shows the extraction 
efficiencies as illustrated in figure 4.3.5 were 30-48%, 86–95%, 60–70% and 30–
60% for 50 µL, 100 µL, 150 µL and 200 µL, respectively.  The optimum volume for 
the extraction was found to be 100 µL. Volumes above 100 µL resulted in decreasing 
extraction effeciencies. A volume of 100 µL of dichloromethane was therefore used 
for all further extractions. 
 
 
 
Figure 4.3.5 Extraction solvent volume optimization 
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4.4 DLLME method validation 
The European Union (EU) Commission Decision 2002/657/EC Directive, that defines 
performance criteria for validation of analytical methods were used for DLLME 
method validation [26].  Several validation parameters such as precision, limit of 
detection (LOD), limit of quantification (LOQ), decision limit (CCα), detection 
capability (CCβ), linearity, and recovery were determined under the optimized 
conditions. 
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Table 4.4.1: Summary of limit of detection (LOD) and limit of quantification (LOQ)  
Analyte R2 LOD 
(µg kg-1) 
n = 8 
LOQ 
(µg kg-1) 
n = 8 
Cimaterol 0.9942 0.0738 0.246 
Cimbuterol 0.9952 0.0738 0.246 
Clenbuterol 0.9930 0.0781 0.260 
Clenproperol 0.9948 0.0756 0.252 
Isoxsuprine 0.9917 0.0922 0.307 
Ractopamine 0.9915 0.0884 0.295 
Ritodrine 0.9756 0.0728 0.243 
 
Limit of detection was calculated as LOD = 3.3*(sy/m) and limit of quantification as 
LOQ = 10*(sy/m) where m is the slope of the calibration curve and Sy is the standard 
error of the calibration curve given by the equation below; 
 
 
 
Where: Yi is the y value, Xi is the x value, b is the y intercept, m is the slope and n is 
number of the degrees of freedom. 
 
The R2 LODs and LOQs of all beta-agonists are summarized in Table 4.4.  All the 
LODs and LOQs are below the MRL levels for these drugs and ranged from 0.0728-
0.0922 and 0.243 – 0.307 respectively which makes the developed method (DLLME) 
more suitable for its desired goal and its application in routine analysis.   
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The DLLME as an extraction method was applied to bovine samples spiked with 
beta-agonist to validate the method. Linearity was determined using pre-extraction 
matrix spikes which are samples that were spiked with beta-agonists standards 
solutions prior to extraction. It was very important to use matrix calibration standards 
to minimize matrix effects and improve the method precision. Linearity in the range 
of 0.5 – 2.0 µg kg-1 was obtained with regression coefficients indicated in Table 4.4.1.   
 
For precision batches, four controls for each analytical batch were prepared.  Each 
spiking level had seven replicates except for the blank (a batch).  Bovine muscle 
samples were spiked at 0.5 x MRL (spike 1), 1 x MRL (spike 2), 1.5 MRL (spike 3) 
and a blank sample.  The experiment was repeated on two occasions.  The spiked 
bovine muscle samples after processing through DLLME sample, were analyzed by 
+ESI LC-MS/MS in MRM scan mode.  The data obtained was then used to calculate 
the validation parameters i.e. limit of detection (LOD), limit of quantification (LOQ), 
CCα and CCβ. 
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Table 4.4.2. Accuracy and precision of the DLLME  
 
Analyte Spiking 
Level 
(ug/Kg) 
Mean 
 (n= 21) 
recovery 
(%) 
Maximum 
Recovery (%) 
 
Minimum 
Recovery 
(%) 
CV (%)  
 
Cimaterol 0.50 
0.75 
1.0 
93 
98 
100 
102 
107 
108 
86 
90 
93 
5 
7 
5 
Cimbuterol 0.50 
0.75 
1.0 
95 
96 
96 
104 
105 
107 
84 
87 
86 
6 
7 
8 
Clenbuterol 0.50 
0.75 
1.0 
94 
96 
91 
100 
107 
95 
83 
84 
86 
5 
8 
3 
Clenproperol 0.50 
0.75 
1.0 
93 
99 
91 
105 
108 
98 
84 
86 
86 
6 
7 
4 
Isoxsuprine 0.50 
0.75 
1.0 
92 
92 
93 
98 
104 
103 
84 
84 
87 
5 
8 
6 
Ractopamine 0.50 
0.75 
1.0 
92 
95 
91 
100 
104 
101 
82 
88 
84 
5 
6 
6 
Ritodrine 0.50 
0.75 
1.0 
91 
89 
92 
99 
99 
104 
81 
85 
86 
5 
5 
7 
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The validation results shown in Tables 4.4.2. and 4.4.3  The mean recoveries of 
spiked blank muscle samples at three levels (i.e. 0.5, 0.75 and 1.0 µg kg-1) ranged 
from 85 to 108% and the reproducibility was between 2 and 7.  The recoveries were 
satisfactory as they are within the acceptable range of 80 – 110% and the method is 
reproducible (% CV are less than 23) according to the EU Commission Decision 
2002/657/EC Directive. 
 
The method performance characteristics (decision limit and detection capacity) were 
also determined.  The decision is defined as the limit above which it can be 
concluded, with an error probability of α, that a sample is non-compliant (higher than 
the MRL), and detection capability is defined as the smallest content of the 
substance that may be detected, identified and quantified in a sample with an error 
probability of β.  The decision limit, CCα was calculated as the mean measured 
concentration at MRL +1.64x in-house reproducibility at this concentration and  the 
detection capacity, CCβ was calculated as CCα+1.64 x the in-house reproducibility 
at MRL.  The obtained CCα ranged from 0.492 to 0.559 µg kg-1 while CCβ ranged 
from 0.509 to 0.615 µg kg-1. 
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Table 4.4.3: The validated parameters for the DLLME method 
Analytes Cimaterol Cimbuterol Clenbuterol Clenproperol Isoxsuprine Ractopamine Ritodrine 
Spiked at 
0.5 ug/kg 
0.50 0.50 0.50 0.50 0.50 0.50 0.50 
Mean (n= 21) 
recovery 
(%) 
93 95 94 93 92 92 91 
Maximum  
Recovery (%) 
 
102 104 100 105 98 100 99 
Minimum 
Recovery (%) 
86 84 83 84 84 82 81 
CV (%)  5 6 5 6 5 5 5 
Mean conc. 
At MRL 
0.521 0.474 0.464 0.467 0.459 0.460 0.456 
Reproducibility 
at MRL 
0.022 0.011 0.031 0.028 0.022 0.047 0.0252 
CCα (µg kg-1) 0.559 0.492 0.515 0.513 0.495 0.537 0.498 
CCβ (µg kg-1) 0.596 0.509 0.565 0.560 0.531 0.615 0.539 
LOD (µg kg-1) 0.0738 0.0738 0.0781 0.0756 0.0922 0.0884 0.0728 
LOQ (µg kg-1) 0.246 0.246 0.260 0.252 0.307 0.295 0.243 
R2 0.9942 0.9952 0.9930 0.9948 0.9917 0.9915 0.9756 
 
 
4.4.1.1 Comparison of DLLME and dSPE 
Sample preparation for determination of beta-agonists in bovine muscle by DLLME 
method was compared to dispersive solid phase extraction clean up method for the 
latter (Table 4.4.4).   
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The recoveries from spiked bovine muscle for both DLLME and dSPE are given in 
Table 4.4.4.  The mean extraction recoveries for DLLME obtained were between 85 
to 100% whereas that of dSPE was found to be between 77 to 91%.  A paired t-test 
was performed for the two methods.  For four out of the seven beta-agonists, DLLME 
performed better than dSPE, and there was no significant difference for the 
remaining three compounds.  Considering the amount (large volumes on 
comparative basis) of organic solvents used for dSPE technique, DLLME has 
demonstrated to be a better sample preparation technique with respect to 
environmental friendliness since less of organic solvents were used, (in microliters 
volumes).  The extraction time in DLLME is shorter and this method does not involve 
any labor-intensive and time consuming steps.  
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Table 4.4.4. The recoveries of DLLME and dSPE 
Analyte Amount 
added Spiked 
(µg kg-1) 
N Mean  (% 
recovery) 
DLLME 
Mean (% 
recovery) 
dSPE 
CV (%) 
DLLME 
CV (%) 
SPE 
 
Cimaterol 
0.50 7 99 83 6 7 
0.75 7 98 89 7 7 
1.00 7 100 85 5 7 
Cimbuterol 0.50 7 92 84 6 7 
0.75 7 96 84 7 10 
1.00 7 96 91 8 9 
Clenproperol 0.50 7 96 91 6 9 
0.75 7 99 91 7 6 
1.00 7 91 85 4 11 
Clenbuterol 0.50 7 89 88 6 11 
0.75 7 96 81 8 4 
1.00 7 91 82 3 11 
Isoxsuprine 0.50 7 93 89 8 4 
0.75 7 92 87 8 8 
1.00 7 93 86 6 8 
Ractopamine 0.50 7 90 93 10 9 
0.75 7 95 89 6 8 
1.00 7 91 77 6 3 
Ritodrine 0.50 7 91 84 8 7 
0.75 7 85 85 5 7 
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Analyte Amount 
added Spiked 
(µg kg-1) 
N Mean  (% 
recovery) 
DLLME 
Mean (% 
recovery) 
dSPE 
CV (%) 
DLLME 
CV (%) 
SPE 
1.00 7 94 82 7 6 
 
N = number of replicates 
SD = standard deviation of 7 replicates 
CV = (SD/mean)*100 
 
 
4.4.2  Application of the validated DLLME method in bovine muscle 
The optimized and validated DLLME method was used to analyze 26 bovine muscle 
samples.  In 21 out of 26 samples, none of beta-agonists compounds were detected 
whereas, in 5 samples, clenbuterol (0.344 µg kg-1, 0.421 µg kg-1), Isoxsuprine (0.249 
µg kg-1, 0.288 µg kg-1) and Ractopamine (0.582 µg kg-1) clenbuterol were detected 
and quantified.  This means there was illegal dosage of these drugs in meat 
producing animal, in Botswana, despite the substances being banned. 
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Table 4.4.5  Bovine muscle samples analysed by the validated DLLME method. 
 
Analytes Cimaterol Cimbuterol Clenbuterol Clenproperol Isoxsuprine Ractopamine Ritodrine 
Spiked at 
0.5 µg kg-1 (3 
spikes) 
0.50 0.50 0.50 0.50 0.50 0.50 0.50 
Spike 1  
recovery (%) 
96 93 87 86 89 98 94 
Spike 2  
recovery (%) 
 
87 84 90 85 95 103 91 
Spike 3 
Recovery (%) 
83 89 87 94 91 88 97 
Sample 1 - - 0.344 - - - - 
Sample 2 - - - - - - - 
Sample 3 - - - - 0.249 - - 
Sample 4 - - - - - - - 
Sample 5 - - - - - - - 
Sample 6 - - - - 0.288  - 
Sample 7 - - - - - - - 
Sample 8 - - - - - 0.582 - 
Sample 9 - - - - - - - 
Sample 10 - - 0.421 - - - - 
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CHAPTER FIVE 
 
5.0 Conclusions 
The objectives of the research were achieved with the following specific objectives 
completed: The mass spectrometry method was successfully developed and 
optimized for the determination of beta-agonists.  The separation method was also 
successfully developed for seven beta-agonists compounds in bovine muscle.  
Dispersive liquid-liquid microextraction (DLLME)  was also successfully developed,  
optimized and validated for the extraction of seven beta-agonists (Cimaterol, 
Cimbuterol, Clenproperol, Clenbuterol, Ractopamine, Isoxsuprine and Ritodrine) in 
bovine muscle using a Applied Biosystem 4000 Qtrap mass spectrometer for the 
simultaneous detection and identification  in single analysis. 
 
Validation of the optimized DLLME method was done according to the Commission 
Decision 2002/657/EC and ISO 17025.  The validated DLLME method was then 
applied on real samples (bovine muscle). An environmentally friendly sample 
preparation method (DLLME) for simultaneous determination of seven beta-agonists 
in bovine muscle by +ESI-LC-MS/MS was developed.  This method is simple, cheap 
and it is short. The sensitivity of this method was proven, since it is capable of testing 
at levels below the appropriate Minimum Performance Residue Limits (MPRLs) for 
the beta-agonists (0.5 µg kg-1).The method was applied to 26 bovine muscle 
samples collected from two Botswana Meat Commission abattoirs (BMCs).  
 
In 21 of the 26 samples, no beta-agonists were found.  In the other 5 samples, 
clenbuterol was detected in two samples (one sample gave 0.344 µg kg-1and 
51 
 
another gave 0.421 µg kg-1). Also Isoxsuprine was detected in two samples (one 
sample gave 0.249 µg kg-1while another gave 0.288 µg kg-1) and Ractopamine 
(0.582 µg kg-1) were detected and quantified.  The implication is that some of these 
drugs are being used by some Botswana farmers for medicinal purposes.  
 
The analytical method (optimized DLLME) in the present study was validated using 
ISO 17025 and the EU criteria (Commission Decision 2002/657/EC).  Good 
precision, repeatability and recoveries were obtained.  The limits of detection and 
quantification for the residues were between 0.0792 – 0.122 µg kg-1and 0.264 – 
0.408 µg kg-1respectively for the seven beta-agonists.  The overall recoveries were 
between 85% and 100% with the relative standard deviations (RSDs) between 3.0% 
and 10%.  The recoveries from dispersive liquid-liquid micro-extraction (DLLME), 
85% to 100% were comparable to those of dSPE (77% to 93%).  Also the Decision 
limit (CCα) and Detection capability (CCα) were calculated.  For cimaterol, [(CCα) was 
0.559, above this level the sample is non-compliant and (CCβ) was 0.596 being 
detection capability].  The DLLME method was used to test bovine muscle samples 
from BMC, and low concentrations of some of beta-agonists were accurately 
determined showing the sensitivity of this method.  
 
5.2 Recommendation 
The recommendation for future research on this subject, the limit of detection (LOD) 
and limit of quantification (LOQ) of analysis for beta-agonists in bovine muscle by 
DLLME can be improved by the use of surfactants, since most cases the muscle 
samples have some fats, which give a problem.  This method can be used in routine 
laboratory analysis of beta-agonists for surveillance purposes.  More sampling from 
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Botswana slaughter houses is recommended since some traces of these prohibited 
drugs were detected. 
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